

## Research Article

## The protective effect of *Ginkgo biloba* leaves extract against liver toxicity in comparison with anti-fibrotic drug in male rats

Maher A.A. Amer<sup>1</sup>, Sameh Shabana<sup>1</sup>, Yasmina A.A. El-Tahry<sup>1</sup>, Fatma A. keshk<sup>1</sup><sup>1</sup>Zoology Department, Physiology Division, Faculty of Science, Mansoura University, Egypt

\*Corresponding Author

Maher Amer Ali Amer

**Abstract: Background:** The rising numbers of patients with liver injury caused by many reasons such as usage of drugs, alcohol and malnutrition which induced an excessive production of free radicals that are responsible for several liver diseases, recent investigations have proved the important role of antioxidants to ameliorate the damage caused by these compounds. In addition, there is a great attention for usage of herbal medicine in treatment of liver disease. **Objective:** The present comparative study was carried out to evaluate the hepato-protective effect of *Ginkgo biloba* leaf extract (GbE) against hepatotoxicity induced experimentally by CCl<sub>4</sub> and comparing these effects with a reference drug (Legalon) that used commonly in Egypt to treat liver disorders. **Methods:** Animals were treated orally with GbE at a dose of (100ml/kg) and Legalon drug at a dose (100ml/kg), once daily for one week before the first dose of CCl<sub>4</sub>. Thereafter, liver fibrosis was induced by oral administration of CCl<sub>4</sub> at a dose of (2.5 ml/kg) in olive oil day after day for 8 weeks, and the administration of GbE and Legalon was continued at the same doses and duration. At the end of the experiment, haematological changes and transmission electron microscopy for the liver sections were investigated to evaluate the protective effect of GbE. **Results:** showed that CCl<sub>4</sub> induced a significant ( $P>0.5$ ) decrease in RBCs count, Hb content, and platelets count, but WBCs count was significantly increased when compared with control group. On the other hand, treatment with GbE caused alterations to all of these parameters when compared with both CCl<sub>4</sub>-intoxicated group and Legalon group. CCl<sub>4</sub>-intoxication caused loss of the normal structure integrity while liver sections of animals supplemented with GbE against CCl<sub>4</sub>-toxicity showed a remarkable improvement in the liver tissue. **Conclusion:** pre-treatment of the animals with GbE improved the liver damage that induced experimentally by CCl<sub>4</sub>. The hematological parameters and histopathological studies showed that GbE extract have a hepato-protective effect due to its ability to ameliorate the deleterious effect on the structure of the liver, produced by CCl<sub>4</sub>.

**Keywords:** *Ginkgo biloba* leaves extract; Legalon drug; liver toxicity.

### INTRODUCTION

The liver is regarded as the most important between the largest organs in the human body; it is responsible for many functions, such as the process of metabolism which is essential for life (Kandimalla *et al.*, 2016). It's location in the human body make it to be vulnerable to various toxic substances of foreign origin. These xenobiotics pass first through the liver before it's absorption by the intestine that makes it threatened by disease more than any other organ (Stickel *et al.*, 2002).

Liver disease has become a global burden and every year up to 20000 deaths occur due to liver affections (Latha *et al.*, 2009). Liver disease can be

resulted from various mechanisms. A prevalent type of liver disease is viral infection. Viral hepatitis like Hepatitis B virus and Hepatitis C virus can be vertically transferred during birth through contact with infected blood (Benova *et al.*, 2014, Komatsu, 2014). Liver fibrosis refers to the response of the liver to various chronic insults like parasitic disease, chronic viral infection (hepatitis B and C), immunologic attack (autoimmune hepatitis), hereditary metal overload, toxic damage, and so forth. Because of the worldwide spreading of these insults, liver fibrosis is prevalent and is correlated with a great number of morbidity and mortality (Chen *et al.*, 2002, Han, 2002, Shen *et al.*, 2003).

Quick Response Code



Journal homepage:

<http://www.easpublisher.com/easmb/>

Article History

Received: 30.05.2019

Accepted: 15.06.2019

Published: 30.06.2019

Copyright © 2019: This is an open-access article distributed under the terms of the Creative Commons Attribution license which permits unrestricted use, distribution, and reproduction in any medium for non commercial use (NonCommercial, or CC-BY-NC) provided the original author and source are credited.

Hepatotoxicity stimulated by CCl<sub>4</sub> solvent is regarded as common model used to study hepatoprotective potency of natural products (Lu *et al.*, 2016). The latter is a chemical solvent that induce liver injury like that generated by viral hepatitis (Ponmari *et al.*, 2014). CCl<sub>4</sub> arrived to the liver as a foreign toxin and it converted into two free radicals, which are trichloromethyl and trichloromethyl peroxy, through the microsomal system dependent on monooxygenase P-450. Furthermore, these two free radicals elicited the beginning of the oxidation of unsaturated lipids (Zhao *et al.*, 2016). CCl<sub>4</sub> also cause the oxidation of unsaturated lipids leading to generation of hepatic injury (Buege and Aust, 1978). Moreover many compounds are known with their crucial role against liver damage induced by CCl<sub>4</sub> by producing their protective action either by reducing CCl<sub>4</sub> derived free radicals or by their antioxidant activities (Hewawasam *et al.*, 2004).

*Ginkgo biloba* extract is popularly marketed to populate as it has the ability to provide useful improvements in memory impairments, stroke, edema, inflammation, Alzheimer's dementia and vasocclusive disorders (Diamond *et al.*, 2000). *Ginkgo biloba* leaves extract contains several chemical constituents that have been isolated and identified, comprising diterpenes (e.g., ginkgolides A, B, C, and J), sesquiterpenes (e.g., bilobalide), ginkgo flavonol glycosides (e.g., the glycosides of kaempferol, quercetin, and isorhamnetin), triterpenes (e.g., sterols), organic acids, and polyphenols (Beek *et al.*, 1998).

Therefore, the present study has been carried out to investigate the possible ameliorative effect of a plant extract (*Ginkgo biloba* leaves extract) and antifibrotic drug (Legalon) against liver toxicity induced experimentally by carbon tetrachloride in male rats.

## MATERIALS AND METHODS

### Chemicals

CCl<sub>4</sub>, Legalon drug, and *Ginkgo biloba* leaves extract were purchased from Sigma chemicals, Egypt. All other reagents used in this study were of high quality and analytical grade.

### Animals and Experimental Protocol

Adult male albino rats, eight weeks old weighing 100-120 g, were kept under a photoperiod of 12h light: 12h darkness schedule with lights-on from 06.00 to 18.00h. They were housed in stainless cages with air conditioned temperature (22-25°C). The animals received standard laboratory diet composed of 40% crushed corn, 30% feed paddy, 20% grinded soybean, 10% barley, molasses and supplied with water *ad libitum* throughout the experimental period. After 2 weeks of acclimation, rats were divided into seven groups each comprising of eight animals.

### Animal Grouping:

Animals were divided in to seven groups (n=8). **Group I:** control group in which animals didn't receive any treatment. **Group II:** GbE control group in which animals were received GbE orally at a dose (100 mg/kg) day after day for 8 weeks (Welt *et al.*, 2007). **Group III:** Legalon control group that received Legalon at a dose (100mg/kg) day after day for 8 weeks (Roy and Das, 2010). **Group IV:** rats were received CCl<sub>4</sub> dissolved in olive oil (V/V) at a dose (2.5 ml/kg body.wt) orally day after day for 8 weeks (Fischer-Nielsen *et al.*, 1991). **Group V:** animals received GbE and CCl<sub>4</sub> at the same doses mentioned previously. **Group VI:** rats received Legalon and CCl<sub>4</sub>. **Group VII:** animals were administered GbE in addition to Legalon and CCl<sub>4</sub> at the same doses mentioned previously.

### Sampling

At the end of the experimental period (8 weeks), overnight fasted rats were sacrificed and withdrawing blood. The blood samples were collected on EDTA for hematological studies. The liver of each rat was removed then cut into parts and stored in osmium tetroxide (4%) for transmission electron microscopy.

### Measurement of Haematological Parameters

Haematological parameters including the count of red blood corpuscles (RBCs), white blood cells (WBCs), haemoglobin (Hb) concentration and platelets count were conducted using haematological analyzer (Sysnex Ts-21) Japan (Dacie and Lewis, 1991).

### Statistical Analysis:

Results were expressed as means ± SE. Statistical significance was calculated using one way analysis of variance (ANOVA) followed by post comparison was carried out with LSD test using Graph pad prism. Differences were considered significance at  $p \leq 0.05$  (Snedecor and Cochran, 1980).

### Histological and Ultrastructural Methods

Transmission electron microscopy for liver sections was performed as described Masyuk *et al.*, (2014).

## RESULTS

### Evaluation of blood cell indices


Table (1) showed a significant ( $P < 0.05$ ) decrease in RBCs count, platelets count and haemoglobin content in CCl<sub>4</sub>-intoxicated group as compared with control group while, a significant ( $P < 0.05$ ) increase was observed in WBCs count. On contrary, pretreatment with *Ginkgo biloba* leaf extract resulted in improvement in all of blood cell indices when compared with CCl<sub>4</sub>-intoxicated group.

**Table (1): Hematological parameters in control and different treated animal groups:**


Parameters	Animal Groups						
	Control	GbE	L	CCl4	GbE+CCl4	L+CCl4	GbE+L+CCl4
<b>RBCs (10<sup>6</sup>/mm<sup>3</sup>)</b>	5.598±0.4197\	6.140±0.4044	4.700±0.2249	2.463 <sup>a</sup> ±0.1963	4.713 <sup>b</sup> ±0.2052	3.965 <sup>a,b</sup> ±0.175	4.000 <sup>a,b</sup> ±0.2394
<b>WBCs (10<sup>3</sup>/mm<sup>3</sup>)</b>	5.935±0.2384	6.548±0.2442	7.330±0.1945	11.03 <sup>a</sup> ±0.4669	8.470 <sup>a,b</sup> ±0.4218	9.440 <sup>a</sup> ±0.4104	8.948 <sup>a,b</sup> ±0.4777
<b>Platelets count (10<sup>3</sup>/mm<sup>3</sup>)</b>	740.7±21.5	618.1±21.53	575.7±21.53	373.9 <sup>a</sup> ±21.53	560.4 <sup>a,b</sup> ±21.53	476.3 <sup>a,b</sup> ±21.53	498.0 <sup>a,b</sup> ±21.53
<b>Hb content (g/dl)</b>	12.64±0.2031	12.92±0.2031	10.97±0.2031	9.160 <sup>a</sup> ±0.2031	10.90 <sup>ab</sup> ±0.2031	9.978 <sup>a</sup> ±0.2031	10.09 <sup>ab</sup> ±0.2031

Values are presented as means ±SE (n=8rats per each group).

(P<0.05), a= significance as compared with control, b= significance as compared with CCl<sub>4</sub> group. S=serum, H= hepatic.



**Figure (1): (RBCs) 10<sup>6</sup>/mm<sup>3</sup> count and (WBCs) (10<sup>3</sup>/mm<sup>3</sup>) count of control and different animal groups.**



**Figure (2): Platelets count (10<sup>6</sup>/mm<sup>3</sup>) and Haemoglobin (Hb) content (g/dl) of control and different animal groups.**

**Transmission Electron Microscopy Observations:**


The liver sections of the control group showed hepatocytes possess a spherical nucleus with a vascular nucleolus, as well as cell organelle including numerous

mitochondria contained medium density, homogenous matrices and many fine cristae. Endoplasmic reticulum confined to numerous small stakes is detected scattered through the cytoplasm Fig. A. On contrary, hepatocyte



of CCl<sub>4</sub>-induced liver damage showed shrunken of hepatocytes, margination of chromatin, Fatty degeneration, kupffer cells, and clumping of mitochondria Fig. B. Liver sections of GbE treated group showed uniform mitochondrial distributions,

regeneration of rough endoplasmic reticulum and vacuolations in cytoplasm Fig. C. Legalon treated group showed mild migration of chromatin, condensed cytoplasm, and regeneration of rough endoplasmic reticulum Fig. D.



**Figure 3: Transmission electron microscopy of liver sections of the different groups including (A)control group/ (B)CCl<sub>4</sub> intoxicated group / (C) the group pretreated with GbE against CCl<sub>4</sub> intoxication / (D)the group pretreated with Legalon against CCl<sub>4</sub>.**

## DISCUSSION

Hepatotoxicity is known as liver dysfunction or liver damage that is related to high concentrations of drugs or xenobiotics (Navarro and Senior, 2006). The chemicals that induce liver injury are known as hepatotoxins or hepatotoxicants. Hepatotoxicants are exogenous compounds of clinical importance and may comprise high doses of definite medicinal drugs, industrial chemicals, natural chemicals like microcystins, herbal remedies and dietary supplements (Willett *et al.*, 2004).

On the cellular level, liver fibrosis is generated by aggregation of extracellular matrix (ECM) proteins such as collagen and fibronectins, synthesized by hepatic stellate cells (HSC) (Bataller and Brenner, 2005). These activated HSC are featured by increased mRNA expression of transforming growth factor beta (TGF- $\beta$ ), alpha smooth muscle actin ( $\alpha$ -SMA), and collagen. Subsequently, the anti-fibrotic therapies are based on targeting phenotypically activated HSC (ur Rehman *et al.*, 2018). Carbon tetrachloride CCl<sub>4</sub> toxicity leads to oxidative stress which causes not only hepatocytes damage but also causes generation of cytokines such as TGF- $\beta$ . TGF- $\beta$  induces rat HSC and helps them to differentiate into myofibroblast-like cells that cause accumulation of ECM and collagen (Jeong *et al.*, 2005). The HSC stimulated by ROS and different cytokines in an accelerated fashion elicited liver fibrosis (ur Rehman *et al.*, 2018).

A small number of drugs are effective in the treatment of chronic liver disease (Muriel and Rivera-Espinoza, 2008). But, their cost is very high and has unavoidable side effects (Fried, 2002). Therefore a great concern is directed to herbal medicines due to their economy, facility of accessibility and little or no side effects. Herbal remedies are widely used by one quarter of hepatic patients (Stickel and Schuppan, 2007). *Ginkgo biloba* (Ginkgoaceae family) contains various phytoactive compounds like flavonoids, terpenelactones, proanthocyanidins, ginkgolic acids, biflavone, and ginkgotoxins (Mahady, 2001). Flavonoids in GbE have the ability to attenuate the tissue damage induced by oxygen-derived free radicals, therefore attenuation of lipid peroxidation (Aljadaani *et al.*, 2016).

It has been observed in our study that oral administration of CCl<sub>4</sub> for 8 weeks significantly affected all hematological parameters including a significant decrease in RBCs count, Hb content, and platelets count, but WBCs count was significantly increased. Our findings are in agreement with that reported by (ur Rehman *et al.*, 2018).

In the present study, it was found that oral administration of *Ginkgo biloba* leaf extract against toxicity induced by CCl<sub>4</sub>, caused amelioration in all hematological parameters, where we observed increasing in the RBCs count, Hb content and platelets count, while WBCs count was reduced. Our results are

in accordance with several results published previously elsewhere (Wang *et al.*, 2015, Aziz *et al.*, 2018).

In the present work Transmission electron microscopy liver sections of animals intoxicated with CCl<sub>4</sub> showed shrunken of hepatocytes, margination of chromatin, Fatty degeneration, kupffer cells, and clumping of mitochondria. While liver sections of rats supplemented with GbE against CCl<sub>4</sub>-intoxication showed uniform mitochondrial distributions, regeneration of rough endoplasmic reticulum and vacuolations in cytoplasm.

#### CONCLUSION:

*Ginkgo biloba* leaves extract caused a protective effect against CCl<sub>4</sub>-induced liver necrosis and fibrosis and exhibited clear liver hepatic recovery characterized by noticed regeneration of hepatocytes and the hepatic tissue appeared more or less normal in most sections, compared with the CCl<sub>4</sub>-induced liver fibrosis group.

#### REFERENCES:

1. ALJADAANI, B., BAKR, A., & HAMZA, A. (2016). Effect of Ginkgo biloba and Commiphora opobalsamum extracts on liver fibrosis and kidney injury induced by carbon tetra chloride in experimental models. *World J Pharm Sci*, 4, 148-152.
2. AZIZ, T. A., HUSSAIN, S. A., MAHWI, T. O., & AHMED, Z. A. (2018). Efficacy and safety of Ginkgo biloba extract as an "add-on" treatment to metformin for patients with metabolic syndrome: a pilot clinical study. *Therapeutics and clinical risk management*, 14, 1219-1226.
3. BATALLER, R., & BRENNER, D. A. (2005). Liver fibrosis. *The Journal of clinical investigation*, 115, 209-218.
4. BEEK, T. A. V., BOMBARDELLI, E., MORAZZONI, P., & PETERLONGO, F. (1998). Ginkgo biloba L. *Fitoterapia*, 68, 195-244.
5. BENOVA, L., MOHAMOUD, Y. A., CALVERT, C., & ABU-RADDAD, L. J. (2014). Vertical transmission of hepatitis C virus: systematic review and meta-analysis. *Clin Infect Dis*, 59, 765-73.
6. BUEGE, J. A., & AUST, S. D. (1978). [30] Microsomal lipid peroxidation. *Methods in enzymology*. Elsevier.
7. CHEN, W.-X., LI, Y.-M., YU, C.-H., CAI, W.-M., ZHENG, M., & CHEN, F. (2002). Quantitative analysis of transforming growth factor beta 1 mRNA in patients with alcoholic liver disease. *World journal of gastroenterology*, 8, 379.
8. DACIE, J., & LEWIS, S. (1991). *Practical Textbook of Haematology 7th Edition* Edinburgh. Church Livingstone.
9. DIAMOND, B. J., SHIFLETT, S. C., FEIWEL, N., MATHEIS, R. J., NOSKIN, O., RICHARDS, J. A., & SCHOENBERGER, N. E. (2000). Ginkgo biloba extract: Mechanisms and clinical indications. *Archives of Physical Medicine and Rehabilitation*, 81, 668-678.
10. FISCHER-NIELSEN, A., POULSEN, H. E., HANSEN, B., HAGE, E., & KEIDING, S. (1991). CCl<sub>4</sub> cirrhosis in rats: irreversible histological changes and differentiated functional impairment. *Journal of hepatology*, 12, 110-117.
11. FRIED, M. W. (2002). Side effects of therapy of hepatitis C and their management. *Hepatology*, 36, S237-S244.
12. HAN, D.-W. (2002). Intestinal endotoxemia as a pathogenetic mechanism in liver failure. *World Journal of Gastroenterology*, 8, 961.
13. HEWAWASAM, R., JAYATILAKA, K., PATHIRANA, C., & MUDDUWA, L. (2004). Hepatoprotective effect of Epaltes divaricata extract on carbon tetrachloride induced hepatotoxicity in mice. *Indian Journal of Medical Research*, 120, 30-34.
14. JEONG, D.-H., LEE, G.-P., JEONG, W.-I., DO, S.-H., YANG, H.-J., YUAN, D.-W., PARK, H.-Y., KIM, K.-J., & JEONG, K.-S. (2005). Alterations of mast cells and TGF-β1 on the silymarin treatment for CCl<sub>4</sub>-induced hepatic fibrosis. *World journal of gastroenterology: WJG*, 11, 1141.
15. KANDIMALLA, R., KALITA, S., SAIKIA, B., CHOUDHURY, B., SINGH, Y. P., KALITA, K., DASH, S., & KOTOKY, J. (2016). Antioxidant and hepatoprotective potentiality of *Randia dumetorum* Lam. leaf and bark via inhibition of oxidative stress and inflammatory cytokines. *Frontiers in pharmacology*, 7, 205.
16. KOMATSU, H. (2014). Hepatitis B virus: where do we stand and what is the next step for eradication? *World Journal of Gastroenterology: WJG*, 20, 8998.
17. LATHA, T., SRIKANTH, A., KUMAR, E., MASTAN, S., SRINIVASA RAO, Y., & BHAVANI, B. (2009). Comparative hepatoprotective efficacy of kumaryasava and Livfit against carbon tetrachloride induced hepatic damage in rats. *Pharmacologyonline*, 1, 1127-1134.
18. LU, Y., HU, D., MA, S., ZHAO, X., WANG, S., WEI, G., WANG, X., WEN, A., & WANG, J. (2016). Protective effect of wedelolactone against

- CCI4-induced acute liver injury in mice. *International immunopharmacology*, 34, 44-52.
19. MAHADY, G. B. (2001). Ginkgo biloba: a review of quality, safety, and efficacy. *Nutrition in Clinical Care*, 4, 140-147.
20. MASYUK, T. V., LEE, S.-O., RADTKE, B. N., STROOPE, A. J., HUANG, B., BANALES, J. M., MASYUK, A. I., SPLINTER, P. L., GRADILONE, S. A., & GAJDOS, G. B. (2014). Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression. *The American journal of pathology*, 184, 110-121.
21. MURIEL, P. & RIVERA-ESPINOZA, Y. 2008. Beneficial drugs for liver diseases. *Journal of Applied Toxicology: An International Journal*, 28, 93-103.
22. NAVARRO, V. J., & SENIOR, J. R. (2006). Drug-related hepatotoxicity. *N Engl J Med*, 354, 731-9.
23. PONMARI, G., ANNAMALAI, A., GOPALAKRISHNAN, V. K., LAKSHMI, P., & GURUVAYOORAPPAN, C. (2014). NF- $\kappa$ B activation and proinflammatory cytokines mediated protective effect of *Indigofera caerulea* Roxb. on CCl4 induced liver damage in rats. *International immunopharmacology*, 23, 672-680.
24. ROY, C. K., & DAS, A. K. (2010). Comparative evaluation of different extracts of leaves of *Psidium guajava* Linn. for hepatoprotective activity. *Pakistan journal of pharmaceutical sciences*, 23.
25. SHEN, L., FAN, J.-G., SHAO, Y., ZENG, M.-D., WANG, J.-R., LUO, G.-H., LI, J.-Q., & CHEN, S.-Y. (2003). Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. *World Journal of Gastroenterology: WJG*, 9, 1106.
26. SNEDECOR, G., & COCHRAN, W. (1980). Correlation. *Statistical methods*, 7, 175-193.
27. STICKEL, F., BRINKHAUS, B., KRÄHMER, N., SEITZ, H., HAHN, E., & SCHUPPAN, D. (2002). Antifibrotic properties of botanicals in chronic liver disease. *Hepato-gastroenterology*, 49, 1102-1108.
28. STICKEL, F., & SCHUPPAN, D. 2007. Herbal medicine in the treatment of liver diseases. *Digestive and liver disease*, 39, 293-304.
29. UR REHMAN, A., WAHEED, A., TARIQ, R., ZAMAN, M., & TAHIR, M. J. (2018). Anti-fibrotic effects of *polygonum plebeium* r. br. in CCl4-induced hepatic damage and fibrosis in rats. *Biomedical Research and Therapy*, 5, 2223-2234.
30. WANG, C.-Z., YUAN, J.-J., LI, W.-J., ZHANG, H.-Y. & YE, J.-Z. 2015. In Vivo and In Vitro Toxicity Evaluation of Polyphenols Extracted from *Ginkgo biloba* L. Leaves. *Molecules*, 20, 22257-22271.
31. WELT, K., WEISS, J., MARTIN, R., HERMSDORF, T., DREWS, S., & FITZL, G. (2007). Ginkgo biloba extract protects rat kidney from diabetic and hypoxic damage. *Phytomedicine*, 14, 196-203.
32. WILLETT, K. L., ROTH, R. A., & WALKER, L. (2004). Workshop overview: hepatotoxicity assessment for botanical dietary supplements. *Toxicological Sciences*, 79, 4-9.
33. ZHAO, Q., PENG, Y., HUANG, K., LEI, Y., LIU, H.-L., TAO, Y.-Y., & LIU, C.-H. (2016). *Salvia miltiorrhiza* protects hepatocytes from oxidative stress by attenuating mitochondrial injury. *Evidence-Based Complementary and Alternative Medicine*, 2016.